Hemab Therapeutics closes $346.7M IPO, shares start trading on Nasdaq under COAG

Hemab Therapeutics, a clinical-stage biotech company focused on blood coagulation therapies, completed its upsized initial public offering (IPO) by selling 19,262,500 shares at $18 each, including full exercise of underwriters' options. The IPO raised approximately $346.7 million in gross proceeds. Hemab's shares began trading on the Nasdaq Global Select Market on May 1, 2026, under the ticker symbol COAG. The funds will support Hemab's development of innovative treatments for bleeding and thrombotic disorders, including therapies for Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand Disease.